VivoSeq
Cardiovascular

Heart Failure With Reduced Ejection Fraction

6

Pipeline Programs↗

8

Active Trials↗

8

Companies Involved↗

Heart Failure With Reduced Ejection Fraction is an early-stage landscape with 6 programs across 8 companies. The most active players are Novartis, Vertex Pharmaceuticals, Eli Lilly. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

22/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

2 programs

Phase 1Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2K

Kyungsub Song

2 programs

ApprovedAstraZeneca logo

AstraZeneca

1 program

ApprovedNovo Nordisk logo

Novo Nordisk

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

3 of 4 classified programs — the dominant modality here.

25%ALL OTHERSPeptide125%

Small molecule leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 44% of 9 pipeline programs.

Analysis

Trial Status

11

clinical trials

Recruiting6 · 55%
Completed3 · 27%
Active, not recruiting1 · 9%
Not yet recruiting1 · 9%

Clinical Trials

Trial Activity

11 trials

Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure With Reduced Ejection Fraction: I-I-CAPTAIN-HF
Recruiting·UUniversity of Colorado, Denver·Preclinical·NCT06526988·2,200 enrolled
A Randomized, Parallel Group, Placebo-controlled, Double-blind, Longitudinal, Single Treatment Center, Phase II Proof-of-concept Study to Evaluate the Efficacy and Safety of Lumacaftor in Stable Heart Failure Subjects With Reduced Ejection Fraction
Recruiting·QQanatpharma AG·Phase 2·NCT07695090·60 enrolled
A Multi-center, Randomized, Participant- and Investigator- Blinded, Placebo-controlled Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of HJB647 in Participants With Chronic Stable Heart Failure With Reduced Ejection Fraction
Recruiting·Novartis logoNovartis·Phase 1·NCT07465653·12 enrolled
Personalizing Heart Failure Treatment With Genomics: A Clinical Trial to Understand the Mechanisms and Validate a Polygenic Risk Score for Beta-Blocker Response
Recruiting·UUniversity of Michigan·Approved·NCT07490067·100 enrolled
Hemodynamic-Guided Optimization With the CardioMEMS Device of Patients With Heart Failure and Secondary Mitral Regurgitation Undergoing Mitral Transcatheter Edge-to-Edge Repair With the MitraClip Device
Recruiting·CColumbia University·Preclinical·NCT06241430·60 enrolled
Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure
Recruiting·JJens D Hove, MD,PHD·Preclinical·NCT06423599·100 enrolled
Treatment of Non-ischemic Dilated Cardiomyopathies by Intravenous Infusions of the Extracellular Vesicle-Enriched Secretome of Cardiovascular Progenitor Cells
Active, not recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 1·NCT05774509·11 enrolled
STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure (STEP-DOWN HF Trial)
Not yet recruiting·—·Approved·NCT07631156·80 enrolled
The Effect of Vericiguat on Exercise Hemodynamics and Exercise Tolerance in Patients With Heart Failure and Reduced Ejection Fraction: The EVERHETT-HF Prospective Observational Cohort Study
Completed·—·N/A·NCT07697365·40 enrolled
Emulation of the EMPEROR-Reduced Trial Using Healthcare Claims Data
Completed·BBrigham and Women's Hospital·N/A·NCT07599345·23,955 enrolled
Real-world Adoption of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction in Treatment With Entresto in Romania (REACT-HFrEF-RO)
Completed·Novartis logoNovartis·N/A·NCT07465679·2,508 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)